• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

作者信息

Kastritis E, Leblond V, Dimopoulos M A, Kimby E, Staber P, Kersten M J, Tedeschi A, Buske C

机构信息

Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Department of Hematology, Pitié Salpêtrière Hospital, Pierre and Marie Curie University, UPMC GRC11-GRECHY, Paris, France.

出版信息

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv41-iv50. doi: 10.1093/annonc/mdy146.

DOI:10.1093/annonc/mdy146
PMID:29982402
Abstract
摘要

相似文献

1
Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.华氏巨球蛋白血症：欧洲肿瘤内科学会诊断、治疗及随访临床实践指南
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv41-iv50. doi: 10.1093/annonc/mdy146.
2
Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.原发性皮肤淋巴瘤：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv30-iv40. doi: 10.1093/annonc/mdy133.
3
Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.霍奇金淋巴瘤：ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv19-iv29. doi: 10.1093/annonc/mdy080.
4
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.肝细胞癌：ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv238-iv255. doi: 10.1093/annonc/mdy308.
5
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.转移性非小细胞肺癌：欧洲肿瘤内科学会临床实践诊断、治疗及随访指南
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237. doi: 10.1093/annonc/mdy275.
6
Waldenstrom's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.华氏巨球蛋白血症：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2013 Oct;24 Suppl 6:vi155-9. doi: 10.1093/annonc/mdt298.
7
Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.非上皮性卵巢癌：ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv1-iv18. doi: 10.1093/annonc/mdy001.
8
Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.骨肉瘤：ESMO-儿童癌症-欧洲骨肉瘤协作组诊断、治疗及随访临床实践指南
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv79-iv95. doi: 10.1093/annonc/mdy310.
9
Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.软组织和内脏肉瘤：ESMO-EURACAN诊断、治疗及随访临床实践指南
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv51-iv67. doi: 10.1093/annonc/mdy096.
10
Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.胃肠道间质瘤：ESMO-EURACAN诊断、治疗及随访临床实践指南
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv68-iv78. doi: 10.1093/annonc/mdy095.

引用本文的文献

1
[Staging and treatment response assessment with radiological and nuclear medicine approaches for non-Hodgkin lymphomas].[非霍奇金淋巴瘤的放射学和核医学分期及治疗反应评估]
Radiologie (Heidelb). 2025 May 28. doi: 10.1007/s00117-025-01459-5.
2
Review of BCL2 inhibitors for the treatment of Waldenström's macroglobulinaemia and non-IgM lymphoplasmacytic lymphoma.用于治疗华氏巨球蛋白血症和非IgM淋巴浆细胞淋巴瘤的BCL2抑制剂综述
Front Oncol. 2024 Nov 4;14:1490202. doi: 10.3389/fonc.2024.1490202. eCollection 2024.
3
Ibrutinib as treatment for Bing-Neel syndrome reclassified as glioblastoma: a case report.
伊布替尼治疗 Bing-Neel 综合征重新分类为胶质母细胞瘤：病例报告。
J Med Case Rep. 2024 Sep 11;18(1):424. doi: 10.1186/s13256-024-04757-z.
4
A phase 2, open-label study of ibrutinib plus rituximab in Japanese patients with Waldenstrom's macroglobulinemia.一项评估伊布替尼联合利妥昔单抗治疗日本华氏巨球蛋白血症患者的 2 期、开放性研究。
Int J Hematol. 2024 Jul;120(1):80-90. doi: 10.1007/s12185-024-03761-9. Epub 2024 Apr 10.
5
Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia.布鲁顿酪氨酸激酶抑制：治疗华氏巨球蛋白血症的有效策略。
Curr Hematol Malig Rep. 2024 Jun;19(3):120-137. doi: 10.1007/s11899-024-00731-0. Epub 2024 Mar 27.
6
Long-term outcomes by bone marrow B-cell depletion from the R2W trial of bortezomib with cyclophosphamide and rituximab in Waldenstrőm macroglobulinaemia.硼替佐米联合环磷酰胺和利妥昔单抗治疗 Waldenström 巨球蛋白血症的 R2W 试验中骨髓 B 细胞耗竭的长期结果。
Leukemia. 2024 Apr;38(4):822-828. doi: 10.1038/s41375-024-02162-5. Epub 2024 Feb 26.
7
Ibrutinib Efficacy, Safety, and Pharmacokinetics in Chinese Patients with Relapsed or Refractory Waldenström's Macroglobulinemia: A Multicenter, Single-Arm, Phase 4 Study.伊布替尼在中国复发或难治性华氏巨球蛋白血症患者中的疗效、安全性及药代动力学：一项多中心、单臂、4期研究。
Adv Ther. 2024 Feb;41(2):672-685. doi: 10.1007/s12325-023-02720-w. Epub 2023 Dec 11.
8
Advances in Treatment of Waldenström Macroglobulinemia.华氏巨球蛋白血症的治疗进展
Curr Oncol Rep. 2023 Nov;25(11):1375-1386. doi: 10.1007/s11912-023-01459-5. Epub 2023 Oct 19.
9
Orbital Infiltration in a Patient with Waldenström Macroglobulinemia: Need for Multidisciplinary Approach and Comparison with the Literature.一名华氏巨球蛋白血症患者的眼眶浸润：多学科方法的必要性及与文献的比较
Mediterr J Hematol Infect Dis. 2023 May 1;15(1):e2023028. doi: 10.4084/MJHID.2023.028. eCollection 2023.
10
MYD88 L265P Mutation Detection by ddPCR: Recommendations for Screening and Minimal Residual Disease Monitoring : ddPCR for Highly Sensitive Detection of MYD88 L265P Mutation.采用 ddPCR 技术检测 MYD88 L265P 突变：筛查和微小残留病监测的推荐方法：ddPCR 技术用于高度敏感检测 MYD88 L265P 突变。
Methods Mol Biol. 2023;2621:57-72. doi: 10.1007/978-1-0716-2950-5_5.